Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00657241 · ClinicalTrials.gov registry record · Phase 3

Cardioprotective Benefits of Carvedilol-CR or Valsartan Added to Lisinopril

A Phase 3 study of Hypertension, sponsored by State University of New York at Buffalo.

Completed
Registry status
Phase 3
Development phase
30
Enrollment target
1
Study location

NCT00657241: Completed Phase 3 study of Hypertension, sponsored by State University of New York at Buffalo.

NCT00657241 is a Phase 3 study of Hypertension that has completed, run by State University of New York at Buffalo. The registered enrollment target is 30 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00657241, a Phase 3 study of Hypertension, has completed, sponsored by State University of New York at Buffalo.

COMPLETED
Registry status
Phase 3
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

14-week single blind, double baseline, forced-titration, cross-over comparison of the cardiac benefits of Coreg CR compared to valsartan added to existing ACE inhibition

Primary Outcome

Cardiac time-tension index (CTTI) is a refined version of the rate-pressure product (RPP, historically systolic \[S\] BP x heart rate) reported by the SphygmoCor pulse wave analysis system used in this trial. CTTI is preferable to RPP because the latter overestimates the contribution of systolic BP to cardiac work (the formula intrinsically assumes maximum SBP throughout the entire heart period \[RR interval\]). In contrast, CTTI represents cardiac work during the actual systolic time interval (

Conditions Studied

Hypertension

Interventions

  • DRUG Valsartan
  • DRUG Carvedilol CR

Study Locations (1)

New York

  • Erie County Medical Center - Buffalo

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2008-04
Est. Completion 2010-04
Phase Phase 3
State University of New York at Buffalo

243 total trials

What the finished NCT00657241 record still lists

NCT00657241 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Valsartan is the first listed.

NCT00657241 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT00657241 about?

NCT00657241 is a clinical study titled "Cardioprotective Benefits of Carvedilol-CR or Valsartan Added to Lisinopril". 14-week single blind, double baseline, forced-titration, cross-over comparison of the cardiac benefits of Coreg CR compared to valsartan added to existing ACE inhibition

What is the current status of trial NCT00657241?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2008-04. Estimated completion is 2010-04.

What conditions does trial NCT00657241 study?

This clinical trial studies the following conditions: Hypertension.

What interventions are being tested in trial NCT00657241?

The interventions under investigation include: Valsartan (DRUG), Carvedilol CR (DRUG).

Who is sponsoring clinical trial NCT00657241?

This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00657241 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00657241's enrollment target sits among peer trials

30 408th of 470 higher than 54 of 470 other Hypertension trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00657241, the US trial registry maintained by the National Library of Medicine. NCT00657241 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.